Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

HDL from patients with type 2 diabetes show a significant reduction of their endothelium-dependent vasodilatory effect.

The primary objective of the study is to analyze whether treatment with glitazones (pioglitazone and rosiglitazone)may improve the endothelium-dependent vasodilatory effect of HDL lipoproteins in patients with type 2 diabetes.

The secondary objectives are:

• to analyze the effect of glitazone treatment on phospholipase A2

• to look for possible differences between the effects of pioglitazone and those of rosiglitazone

• to analyze the glycemic response to glitazone therapy according to clinical and biological baseline characteristics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire Dijon
• Treatments: Pioglitazone; Rosiglitazone

Criteria

Inclusion Criteria:

• patients with type 2 diabetes treated by oral antidiabetic agents (except glitazones) and/or insulin

• age> 18 years

• HbA1c > 6.5%

Exclusion Criteria:

• renal failure

• heart failure

• primary hyperlipidemia

• pregnancy

• treatment that may modify lipid metabolism (glucocorticoids, oestrogens, retinoids, HIV antiviral drugs)